Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | WebDisclosure

Basculer en Français

10681	Companies
228020	Keywords
156520	Articles
120880	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

PRESS RELEASE

published on 09/15/2025 at 16:45, 9 months 20 days ago

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
Protagonist Therapeutics to present Phase 2b ANTHEM-UC study data on targeted oral peptide icotrokinra at UEGW Week 2025 in Berlin. Company focuses on advanced therapies in ulcerative colitis

Ulcerative Colitis Protagonist Therapeutics Icotrokinra Phase 2b ANTHEM-UC Study UEGW Week 2025
BRIEF

published on 09/11/2025 at 14:05, 9 months 24 days ago

Un acteur majeur sollicite l'approbation de l'EMA pour l'icotrokinra dans le traitement du psoriasis

Essais Cliniques Icotrokinra Psoriasis En Plaques Efficacité Du Traitement Demande D'admission À L'EMA
BRIEF

published on 09/11/2025 at 14:05, 9 months 24 days ago

Protagonist Seeks EMA Approval for Icotrokinra in Psoriasis

Clinical Trials Plaque Psoriasis Icotrokinra Treatment Efficacy EMA Application
PRESS RELEASE

published on 09/11/2025 at 14:00, 9 months 24 days ago

Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
Protagonist Therapeutics submits application to EMA for first approval of icotrokinra, an investigational targeted oral peptide blocking IL-23 receptor in plaque psoriasis treatment

Protagonist Therapeutics Plaque Psoriasis Treatment IL-23 Receptor Icoktrokinra EMA Submission
BRIEF

published on 08/26/2025 at 22:10, 10 months 10 days ago

Protagonist Therapeutics Engages in Key Investment Conferences

Clinical Trials Protagonist Therapeutics Investment Conferences Biopharmaceutical Development Icotrokinra And Rusfertide
BRIEF

published on 08/26/2025 at 22:10, 10 months 10 days ago

Protagonist Therapeutics participe à des conférences d'investissement clés

Essais Cliniques Thérapeutique Protagoniste Conférences D'investissement Développement Biopharmaceutique Icotrokinra Et Rusfertide
PRESS RELEASE

published on 08/26/2025 at 22:05, 10 months 10 days ago

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
Protagonist Therapeutics announced CEO's participation in investment bank conferences in September. Company's advanced Phase 3 clinical development and future plans highlighted

Protagonist Therapeutics Phase 3 Clinical Development NDA Submission Investment Bank Conferences Drug Discovery Programs
BRIEF

published on 08/25/2025 at 13:05, 10 months 11 days ago

Le Rusfertide de Protagonist Therapeutics reçoit la désignation de thérapie révolutionnaire de la FDA

Rusfertide Thérapeutique Protagoniste Polyglobulie Vraie Thérapie Révolutionnaire Phase 3 VÉRIFIER
BRIEF

published on 08/25/2025 at 13:05, 10 months 11 days ago

Protagonist Therapeutics' Rusfertide Receives FDA Breakthrough Therapy Designation

Protagonist Therapeutics Rusfertide Polycythemia Vera Breakthrough Therapy Phase 3 VERIFY
PRESS RELEASE

published on 08/25/2025 at 13:00, 10 months 11 days ago

Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
Protagonist Therapeutics' rusfertide granted Breakthrough Therapy Designation by the FDA for polycythemia vera, complementing Orphan Drug and Fast Track designations. NDA filing on track for Q4

FDA Protagonist Therapeutics Rusfertide Breakthrough Therapy Designation NDA Filing

Accesswire

Published on 07/03/2026 at 23:00, 1 day 23 hours ago

Eagle Plains Partner Refined Energy Announces Final Results for Winter 2026 Drill Program at Dufferin West
Published on 07/03/2026 at 23:00, 1 day 23 hours ago

Medicure Announces CFO Change
Published on 07/03/2026 at 21:28, 2 days ago

Trifecta Gold Announces Closing of $1.66 Million Private Placement
Published on 07/03/2026 at 19:30, 2 days 2 hours ago

Polaris Renewable Energy Announces Q2 2026 Investor Call Details
Published on 07/03/2026 at 13:30, 2 days 8 hours ago

Nextech3D.ai Unveils Strategic AI Growth Roadmap Focused on Workforce Intelligence and Event Technology Innovation

View all ACCESSWIRE

EQS Group

Published on 07/05/2026 at 13:45, 8 hours 34 minutes ago

XPPen renforce son engagement en faveur de l’animation grâce à son partenariat avec la Résidence du Festival d’Annecy 2026 et sa présence au MIFA
Published on 07/05/2026 at 13:45, 8 hours 34 minutes ago

XPPen Strengthens Its Commitment to Animation with 2026 Annecy Festival Residency Partnership and MIFA Showcase
Published on 07/04/2026 at 17:35, 1 day 4 hours ago

Vantage Introduces 24/7 Gold CFD Trading with XAUUSD247
Published on 07/04/2026 at 11:01, 1 day 11 hours ago

EQS-Adhoc: Continental AG: Continental AG Sells ContiTech Group Sector
Published on 07/04/2026 at 09:05, 1 day 13 hours ago

Velo x McLaren Mastercard Formula 1® Team Relaunches Live Your Fandom to Bring Fans Closer to the Sport They Love

Les Echos

Published on 07/03/2026 at 21:49, 2 days ago

Safran annonce la fin des négociations concernant le projet d'acquisition d’Exail Technologies.
Published on 07/03/2026 at 21:49, 2 days ago

Safran announces the end of negotiations regarding the contemplated acquisition of Exail Technologies.
Published on 07/03/2026 at 18:42, 2 days 3 hours ago

Total number of voting rights and shares making up the share capital at June 30, 2026
Published on 07/03/2026 at 18:42, 2 days 3 hours ago

Capital et droits de vote au 30 juin 2026
Published on 07/03/2026 at 18:36, 2 days 3 hours ago

Disclosure of transactions in own shares from July 1 to July 3, 2026

View all LES ECHOS COMFI WIRE